Deutsche Bank Maintains Hold On Boston Scientific (BSX)

Deutsche Bank is maintaining its Hold rating and $7.40 price target on shares of Boston Scientific Corporation BSX after the company reported earnings. In a note to clients, Deutsche Bank writes, "BSX has undesirable weightings in declining and/or mature markets due to pricing and/or volume challenges. The 2011 financial guidance is a reminder of such. That said, we view the guidance as achievable, but not without expense mgmt given market conditions. BSX is likely to do more deals and refocus on R&D to diversify its way out (which we see as the best hope for a turnaround). All things considered, absent a major pullback in valuation or sustainable improvement in end markets, we don't view BSX as a good investment as better options exist." Shares of BSX lost 28 cents yesterday to close at $6.85, a loss of 3.9%.